GlassScriptPhysician profile
Thomas W Hiland
NPI 1306815295
$430.41
in general payments reported to CMS, 2019-2025
18 companies · $51.72 in 2025
The $51.72 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.73 · 2021: $27.20 · 2022: $48.79 · 2023: $169 · 2024: $82.03 · 2025: $51.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $302.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $66.57 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $42.01 | 2019-2024 | Farxiga, Airsupra |
| Xeris Pharmaceuticals, INC. | $39.39 | 2023 | Gvoke Hypopen |
| Amgen INC. | $33.23 | 2019-2024 | Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $27.20 | 2021 | |
| Exact Sciences Corporation | $23.35 | 2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $20.70 | 2023 | Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.69 | 2023 | Jardiance, Tradjenta |
| Novartis Pharmaceuticals Corporation | $19.61 | 2023 | |
| Optinose US, INC. | $18.11 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.26 | 2022 | |
| Radius Health, INC. | $15.72 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.88 | 2024 | Voquezna |
| Lilly USA, LLC | $14.68 | 2022 | |
| Glaxosmithkline, LLC. | $14.35 | 2024 | Arexvy, Shingrix |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14.29 | 2023 | |
| Merck Sharp & Dohme LLC | $14.27 | 2025 | Gardasil 9, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $14.10 | 2025 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hiland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.